September 9, 2020

Smart Meter, a diabetes management data, technology and solutions company, announced today that as a result of recent U.S. Federal Drug Administration (FDA) guidance, iGlucose® meters can now be used for individual patients to help reduce infection risk and enable remote patient monitoring (RPM) in long-term care facilities during COVID.

 

Tampa, Fl. – Smart Meter, a diabetes management data, technology and solutions company, announced today that as a result of recent U.S. Federal Drug Administration (FDA) guidance, iGlucose® meters can now be used for individual patients to help reduce infection risk and enable remote patient monitoring (RPM) in long-term care facilities during COVID.

The new guidance, Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency, was issued by the FDA to provide a policy to help expand the availability and capability of non-invasive remote monitoring devices to facilitate patient monitoring while reducing patient and healthcare provider contact and exposure to COVID-19.

Smart Meter’s iGlucose solution provides seamless connectivity to caregivers for RPM. Utilizing the iGlucose platform, blood glucose results and the data is immediately transmitted via AT&T’s vast cellular network to a designated health care provider. The real-time data and ability to communicate with caregivers provides clinicians with an active feedback loop, enabling better, up-to-date recommendations, that can help improve patient outcomes.

According to the American Diabetes Association (ADA), older adults and people living with diabetes have much higher rates of serious complications and death from COVID-19.

“Given that over 30 percent of long-term care residents have diabetes, it is no surprise that we received numerous requests from facilities wanting to use dedicated iGlucose cellular connected meters to reduce infection risk and to keep pace with the shift to remote patient care,” said Brahim Zabeli, Smart Meter CEO. “We are grateful the FDA is allowing the use of home-type meters in long-term care settings during COVID where professional clinical staff may assist a patient in performing a glucose test when needed or requested.”

The iGlucose program features:

Individual patient meters to reduce infection risk and cleaning and disinfection cycles per the Centers for Disease Control and Prevention (CDC).

Automatic glucose result transmission to a secure cloud portal, without cables, docking stations, Bluetooth® pairing or manual entry, which may contribute to fewer errors, omissions, and reduced staff time.
iGlucose portal allows health professionals to remotely monitor glucose trends while informative graphics make it easy to evaluate glucose excursions and, in most cases, utilize billable RPM codes; all without entering the facility thereby limiting potential COVID exposure for both the patient and professional.
Turn-key staff training and logistics for simple initiation.

“Now more than ever, long-term care facilities are looking to intensify efforts in areas of infection control and glycemic management,” says Dr. Jamison Feramisco, CMO, CEO, President and Director at organizations including Alternate Health Corp, ApriHealth, Third Eye Health and Advanced Healthcare Solutions, a few of the many skilled nursing facilities, assisted living facilities, and acute rehabilitation organizations he runs covering over 12 States. “To avoid cross-contamination, dedicated glucose meters have been recommended by the CDC since 2010, while glycemic management has been identified by the ADA as one of the best defenses against poor COVID outcomes. We believe the cellular iGlucose system offers distinct benefits to assist our facilities in both regards as we look to keep our diabetic residents healthy and reduce avoidable hospitalizations during COVID.”

About Smart Meter, LLC
Smart Meter, LLC is a rapidly growing end-to-end solutions provider to businesses in the fast-growing telehealth and remote patient monitoring market. Smart Meter’s cellular-enabled medical devices, data transmission, and digital portals offer significant ease of use and cost-advantages. The iGlucose system is quickly becoming the platform of choice among emerging remote care companies and long-term care facilities during COVID. The patented iGlucose meter transmits real-time glucose results to a HIPPA-compliant cloud portal that provides trends, alerts, and RPM-formatted billing information. The accurate meter features a vibrant color screen, five second test time, and needs only a tiny blood sample. Unlike devices requiring the use of smartphones, apps, Bluetooth, or docking stations, iGlucose seamlessly and automatically transmits information with no user manipulation.

PR Contact
Jennifer Moritz
Zer0 to 5ive
jmoritz@0to5.com
917-748-4006